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Abstract
Intranasally (IN) administered midazolam has allowed patients
who require conscious sedation but struggle to tolerate
cannulation to receive dental treatment under sedation. Studies
have demonstrated a mean bioavailability of 82.4% can be
achieved with IN midazolam due to the high vascularity within
the nose. These studies have also demonstrated that peak plasma
concentrations can be reached within 10 minutes, which signifies
the fast onset of action. The standard bolus dose of IN midazolam
is 10-12mg, which can be reduced or increased depending on the
patient’s age and susceptibility to benzodiazepines. The bolus can
also be repeated if adequate sedation is not reached. Some 17
patients received a standard dose of 10mg of midazolam. There
were two cases of desaturation below 92%, which responded with
oxygen and encouraging the patient to breathe. A protocol for
administering IN midazolam is outlined and two cases are
discussed. 
Introduction
For some people with disability, the continuing management of
oral health including periodontal care, routine examinations and
the provision of restorative treatment is very difficult.1 The use of
conscious sedation in dentistry is one of the most widely
discussed and regulated areas in the profession. In the last twenty
years, there have been many publications providing guidance 
and clinical standards for practice in this area.2 The use of
intravenous midazolam alone is defined as a standard technique.3
Intravenous (IV) sedation using midazolam has had a greatly
positive effect on the provision of dental care; it has improved
access to dental care and reduced reliance on general
anaesthesia. The patient must, however, be able to tolerate
intravenous cannulation, and many patients with disability
struggle with this aspect of conscious sedation. To overcome this
problem, patients with disability were often premedicated with
oral midazolam, but following oral administration it may take up
to 60 minutes to achieve peak plasma concentrations.4 The time
taken to achieve an adequate degree of sedation is frequently
protracted. Oral midazolam is broken down in the liver, and the
first pass reduces its bioavailability to between 35-44%.5
Veldhorst-Janssen et al. have found the mean bioavailability of
intranasal midazolam is approximately 82.4%.6 The main
advantages of intranasal midazolam are, firstly, the high
bioavailability, as the nasal route in not subject to first pass
metabolism,7 and secondly, peak plasma concentration of
midazolam can be reached after 10 minutes.8
Intranasal sedation is not new, but has not been widely adopted
and any method or technique which could help achieve better
treatment outcomes for people with disability should be made
widely available. The technique has been used in some areas of
clinical practice for many years, and in the Special Care
Department of Dorset County Hospital for six months prior to the
preparation of this paper in 2015. 
Clinical pharmacology of midazolam
Midazolam is an imidazobenzodiazepine and is the standard drug
used in the practice of intravenous conscious sedation.9 It has
anxiolytic, sedative, hypnotic, anticonvulsant muscle-relaxant, and
anterograde amnesic effects.10 Midazolam enhances the effect of
GABA, which is an inhibitory neurotransmitter. It also reduces the
excitability of neurones in the brain by increasing the uptake of
chloride ions.11 Midazolam also impairs episodic memory.12
Rationale for the use of the
intranasal route
The nasal route is a very attractive method of delivery due to the
rich vascular plexus (Figure 1) that is present within the nasal
cavity and the ease of accessibility to this vascular bed, allowing
delivery of medications directly to the blood steam.13 Other
techniques of transmucosal sedation, including sublingual, are
described in the literature, but often require a greater degree of
patient cooperation. 
The safest way to administer the agents in conscious sedation is
by titrating them against the patient’s response, and this is the
recommended technique for intravenous sedation with
midazolam. Intranasal administration of midazolam is, in effect, a
bolus dose technique. 
The potential for over-sedation is greater with bolus dose
techniques. It is standard practice that, for all techniques where
midazolam is used to produce conscious sedation, an intravenous
cannula should be placed, as the patient may require reversal. For
this reason, the technique should only be used by dentists and
sedationists who are fully trained and competent in cannulation
and should not be seen as a technique to provide sedation for
patients with difficult IV access. The same standards of monitoring
apply as for intravenous midazolam sedation.
Intranasal Midazolam Dosing
It is widely accepted that the standard dose for IN midazolam is
0.25-0.3mg/kg body weight up to a maximum of 10-12mg given
as a single bolus dose. This bolus can be repeated if the patient is
not adequately sedated. The bolus can also be increased or
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decreased. This bolus dose initially seems very high. Veldhorst-
Janssen found a mean bioavailability of 82.4% for IN administered
midazolam,6 this would equate to a dose of around 8.24mg of
midazolam. This technique has a high record of safety, and
Manley14 conducted an audit of 222 episodes using this technique.
Only one episode of significant desaturation was recorded, which
responded with the administration of oxygen. 
Some patients are tolerant to midazolam. In these patients, the
standard dose may not be sufficient to produce an adequate
degree of sedation to allow dental treatment to be completed. In
some cases, it may be possible to place an intravenous cannula
and titrate midazolam to the endpoint. In others, there may be
insufficient anxiolysis to allow the patient to accept cannulation. 
If the patient cannot accept either cannulation or treatment, it is
often recommended that they are allowed to recover and
reappointed either to have an increased dose of sedative or
treatment under general anaesthesia. 
To allow treatment to proceed as planned, an appropriately
experienced sedationist might consider giving a supplemental
intranasal dose of midazolam. The decision as to whether to give
the additional dose and, if so, how much to give and when, must
be judged by careful patient assessment, including their response
to the initial dose. The potential for over-sedation should not be
underestimated. This procedure should not be a matter of routine,
but a considered judgement taken case-by-case. The second dose
would normally be no greater than 50% of the initial dose. The
authors would only consider using this approach when the
40mg/ml presentation of midazolam is used.
The technique involves the administration of two bolus doses of
midazolam. The advantages of titration vs bolus doses have
already been discussed. The administration of a second bolus dose
will increase rather than decrease the unpredictability. This
technique, whilst practised in a number of centres has not been
the subject of any clinical trials, and so must be viewed as the
personal opinion of the authors. A third dose should not be
administered
Protocol for Intranasal sedation
The patient must go through a pathway of selection, assessment,
history, examination, contraindications and consent. These
processes should follow the IACSD standards15 and are described
in the relevant texts16,17 Table 1, outlines a practical protocol which
can be followed. IN 40mg/ml midazolam + 2mg/ml Lidocaine is
prepared in boxes of five ampoules. Each ampoule has a volume
of 0.5ml, thus 10mg of Midazolam would equate to 0.25ml of
solution. A Luer lock syringe must be used to attach the MAD
device, as this prevents the mucosal atomisation device (MAD)
from detaching during application. 
The MAD is locked onto the syringe and then placed into the right
or left nostril and the bolus is given (Figure 3). It may helpful to
stand behind the patient’s head and use safe holding to gently
brace the head when working with patients who might not be
able to stay still. If given successfully, the effects should occur
within 10-12 minutes, at which point the patient should be
cannulated.  If the sedation is not sufficiently effective after 
12-15 minutes, a decision needs to be taken as to the next course
of action, as described above.
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Figure 1: Figure 1 illustrates the vascular anatomy of the nasal
septal blood supply. A large number of arteries supply the area
and converge to form Kiesselbach’s plexus. 
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Figure 2: IN Midazolam is given as a non-titratable bolus, and
the patient’s response cannot a predicted. 
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Figure 3: An example of IN device being used. 
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Cases
Patient 1
An eighteen-year-old male attended with his parents. He
complained of pain in the lower left quadrant. He presented with
a mobile tender LL4. He also had an UL1 with an incisal edge
fracture. Medically, the patient had adult learning difficulties, was
partially deaf and was undergoing testing for Marfan’s syndrome.
He communicated with sign language and picture cards on his
ipad. All previous treatment had been conducted under general
anaesthetic. 
The options for treatment were discussed, and a treatment plan
was formulated which involved the extraction of the LL4 tooth
and the restoration of the UL1 tooth under conscious sedation
using IN Midazolam. The patient was consented with best
interests.
A 10mg dose of IN midazolam was administered in the right
nostril, and after approximately 12 minutes the patient was
sufficiently sedated to allow cannulation. We were able to extract
the LL4 and restore the UL1 without providing the patient with
supplemental intranasal midazolam or intravenous midazolam.
Pulse, SpO2 and blood pressure remained normal throughout the
treatment. 
Patient 2
A seventy-year-old woman attended the clinic in pain with her
husband, who is her carer. Medically, the patient suffers from
dementia and can only manage to sit down briefly for dental
examinations before getting up and walking around the surgery.
On examination, UR6 was symptomatic. 
Options were discussed. The plan agreed involved extracting the
tooth with IN Midazolam conscious sedation, and if that failed, to
extract the tooth under general anaesthetic. The patient was
consented with best interests. 
A 10mg dose of IN midazolam was administered, and after
approximately 12 minutes the patient was sufficiently sedated to
allow cannulation. The patient was adequately sedated to allow
the extraction of the tooth without the need for additional
intravenous midazolam. Pulse, SpO2 and blood pressure remained
normal throughout the treatment. 
Lessons from these cases histories
These two patients had very different needs. Intranasal midazolam
(40mg/ml midazolam and 20mg/ml lidocaine) is an off-license
medication, and that must be explained and documented as part
of the consent process. The first patient with good support
managed to have dental treatment using intranasal sedation. This
case shows the benefits to both patient and carers. The fact that
the patient was not required to starve made his parents’ lives
much easier. His parents commented that, as treatment was
conducted in familiar surroundings, the episode was less
distressing for their son. 
The second patient, with the help and support of her husband,
managed to have an extraction using intranasal sedation. The
Suggested Sequence Action
1. Carry out pre-sedation checks.
2. Check the ampoule of Midazolam paying attention to the name Midazolam HCl 40mg/ml +
Lidocaine 20mg/ml, Batch number and expire date. 
3. Insert a 1ml Luer locking syringe into the ampule and draw up the decided volume + additional
dead space volume. Carefully label the syringe Midazolam 40mg/ml + Lidocaine 20mg/ml and
dispose of the sharps.
4. Inspect the nostrils for blockages, attach a monitor to the patient to monitor SpO2 and Pulse. 
5. Lock the MAD device onto the Luer lock syringe, place into the patient’s nostril and advise the
patient to sniff as the plunger is pushed. 
6. Continue monitoring the patient’s vital signs for and look for changes in consciousness. 
7. After 10-12 minutes assess the patient for acceptability of intravenous cannulation and dental
treatment.
8. Cannulate patient if sufficiently sedated. If compliant, carry out dental treatment.
9. If the patient tolerates intravenous cannulation, but cannot tolerate the dental treatment consider
adding a titrated dose of intravenous midazolam.
10. If the patient is unable to tolerate intravenous cannulation or dental treatment, consider a second
dose of intranasal midazolam.
Table 1 - Suggested protocol for administering IN conscious sedation. 
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patient’s husband was keen to avoid general anaesthetic for his
wife when we realised that the treatment plan would involve the
extraction of a tooth. The patient was not required to starve prior
to treatment, and the total time in which the patient remained in
the clinic from admission to discharge was significantly shorter
than if she had undergone general anaesthesia. After treatment,
the patient’s husband wrote a thank you card and admitted he
had been sceptical of the technique, but that it had made things
so much easier for both him and his wife. 
There are some patients who will never accept dental treatment
under local anaesthesia without additional pharmacological
intervention. Conscious sedation with intravenous midazolam has
bridged the gap between dental treatment with local anaesthesia
and general anaesthetic, but only if the patient can tolerate
cannulation. A significant number of patients with cognitive
impairment find accepting any form of injection impossible to
tolerate. Both the patients would most likely have been offered
extractions under general anaesthetic as the only option for
treatment. The use of IN sedation in the special care dentistry
department allowed these patients to receive a full spectrum of
dental care. There are also a large number of needle-phobic
individuals for whom IN sedation offers the chance to access
dental care.  
Adverse effects, risks and
contraindications
The risk from IN administered conscious sedation is the same as
for IV midazolam. Some patients have complained of a blocked or
runny nose for 24 hours, and teary eyes. The method is
contraindicated in patients who suffer from nasal polyps, in
patients with cold- and flu-like symptoms, and for patients who
suffer from regular nose bleeds. An absolute contraindication is
that this technique must not be carried out by practitioners who
are not experienced in cannulation, as there would be no way to
reverse the patient if required. It is, however, sometimes difficult to
administer the solution to patients with challenging behaviour.
Training in safe handling is required if considering using this
technique in people with special needs and challenging
behaviour. 
Initial Results
The Special Care Dentistry Department at Dorset County Hospital
has seen great early success with this technique. 17 patients
received a standard dose of 10mg of Midazolam. This was
administered either as a single dose, repeated or used with or
without additional IV midazolam or IV propofol. All the patients
were men and women over the age of twelve and were ASA 1 or
ASA 2. There were two cases of desaturation below 92%, which
responded to oxygen and encouraging the patient to breathe.
Two patients experienced epistaxis: one patient with learning
difficulties placed his fingers in his nose which caused a resultant
bleed, and the other had a spontaneous bleed a few minutes after
the IN bolus was given. 
Flumazenil use
Flumazenil was administered to three patients who had moderate
to severe behavioural difficulties. The patients all had normal vital
signs. Flumazenil was administered to these patients to improve
disorientation rather than reverse any ill effects from over
sedation. As discussed, this technique of conscious sedation is
new to the department and the cohort of patients is very small.
Discussion
The technique involving the titration of intravenous midazolam
has allowed many patients to access dental care, including those
with special needs and needle phobias who have previously been
unable to receive dental treatment with the IV technique. The
intranasal technique could be beneficial to these patients. IN
midazolam application is a basic technique provided that the
practitioner can demonstrate competence in intravenous
sedation.3 The technique of IN sedation is not as widely used as IV
sedation, however, research has found it effective and safe; Manley
et al.14 found that in 222 episodes of sedation, 128 (57.65%)
accepted treatment. 
Conclusion
The purpose of this paper was to demystify the use of IN
midazolam as a technique in conscious sedation. This paper also
outlines a practical protocol which other clinicians could follow in
their own practices for administering IN midazolam. The Special
Care Dentistry Unit at Dorset County Hospital is within a teaching
hospital, and our sedation service is consultant anaesthetist led. At
the time of writing in 2015, the technique had been in use within
the department for a period of six months. The initial results have
been very positive. 
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